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Brief CommunicationBidirectional manipulation of gene expression in
adipocytes using CRISPRa and siRNAMorten Lundh, Kaja Pluciñska, Marie S. Isidor, Patricia S.S. Petersen, Brice Emanuelli*ABSTRACT
Objective: Functional investigation of novel gene/protein targets associated with adipocyte differentiation or function heavily relies on efﬁcient
and accessible tools to manipulate gene expression in adipocytes in vitro. Recent advances in gene-editing technologies such as CRISPR-Cas9
have not only eased gene editing but also greatly facilitated modulation of gene expression without altering the genome. Here, we aimed to
develop and validate a competent in vitro adipocyte model of controllable functionality as well as multiplexed gene manipulation in adipocytes,
using the CRISPRa “SAM” system and siRNAs to simultaneously overexpress and silence selected genes in the same cell populations.
Methods: We introduced a stable expression of dCas9-VP64 and MS2-P65, the core components of the CRIPSRa SAM system, in mesenchymal
C3H/10T1/2 cells through viral delivery and used guide RNAs targeting Pparg2, Prdm16, Zfp423, or Ucp1 to control the expression of key genes
involved in adipocyte differentiation and function. We additionally co-transfected mature adipocytes with sgRNA plasmids and siRNA to
simultaneously up-regulate and silence selected genes. Quantitative gene expression, oxygen consumption, ﬂuorescence-activated cell sorting
and immunocytochemistry served as validation proxies in pre- or mature adipocytes.
Results: CRISPRa SAM-mediated up-regulation of a key adipogenic gene, Pparg2, was successfully achieved using selected sgRNAs targeting
the Pparg2 promoter region (i.e. up to 104 fold); this induction was long lasting and sufﬁcient to promote adipogenesis. Furthermore, co-activation
of Pparg2 with either Prdm16 or Zfp423 transcripts drove distinct thermogenic gene expression patterns associated with increased or decreased
oxygen consumption, respectively, mimicking typical characteristics of brite/beige or white cell lineages. Lastly, we demonstrated that up-
regulation of endogenous genes in mature adipocytes was also easily and efﬁciently achieved using CRISPRa SAM, here exempliﬁed by tar-
geted Ucp1 overexpression (up to 4  103 fold), and that it was compatible with concomitant gene silencing using siRNA, allowing for bidi-
rectional manipulation of gene expression in the same cell populations.
Conclusions: We demonstrate that the CRISPRa SAM system can be easily adopted and used to efﬁciently manipulate gene expression in pre-
and mature adipocytes in vitro. Moreover, we describe a novel methodological approach combining the activation of endogenous genes and
siRNA-mediated gene silencing, thus providing a powerful tool to functionally decipher genetic factors controlling adipogenesis and adipocyte
functions.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fat tissue biology has become of signiﬁcant interest over the last
decades due to its central role in energy homeostasis and obesity-
related metabolic pathology. In vitro models of adipogenesis have
been extensively studied due to the close resemblance between in vitro
adipogenesis and fat cell differentiation in vivo [1]. Adipocytes are
derived from mesenchymal stem cells (MSC) undergoing two distinct
phases: commitment and terminal differentiation. Under speciﬁc
environmental conditions, MSCs initiate adipogenic changes and
become committed preadipocytes. In vitro, this commitment step can
be induced by various hormonal stimuli such as the Bone Morphogenic
Protein (BMP) and TGFb family members, cellecell contacts, or extra
cellular matrix (ECM) composition and stiffness. The adipogenicSection of Integrative Physiology, Novo Nordisk Foundation Center for Basic Metabo
Copenhagen, Denmark
*Corresponding author. University of Copenhagen, Faculty of Health and Medical Scien
Integrative Physiology, Blegdamsvej 3, 07-7-48, DK-2200 N, Copenhagen, Denmark.
Received May 17, 2017  Revision received June 28, 2017  Accepted July 4, 2017
http://dx.doi.org/10.1016/j.molmet.2017.07.001
MOLECULAR METABOLISM 6 (2017) 1313e1320  2017TheAuthors. Published by ElsevierGmbH. This is an o
www.molecularmetabolism.cominduction step from pre- to mature adipocyte can be triggered, at least
in murine cells, by insulin, glucocorticoids, and Protein Kinase A (PKA)
activation [2]. Mechanistically, the terminal differentiation is charac-
terized by the induction of a complex transcriptional program where
the transcription factor Peroxisome proliferator-activated receptor
(PPAR)-g2 is considered a “master regulator” [3]. Thus, Pparg2
expression is both necessary [4] and sufﬁcient [5] to drive adipo-
genesis. Several other transcriptional factors are involved in the
adipogenic process, including the CCAAT-enhancer-binding proteins
(C/EBP) [2,6].
In contrast to classical white adipocytes, which primarily serve for
energy storage, insulation, and adipokine secretion, brown and brite/
beige adipocytes are capable of generating heat by bypassing the
mitochondrial oxidative phosphorylation pathway through expressionlic Research, Faculty of Health and Medical Sciences, University of Copenhagen,
ces, The Novo Nordisk Foundation Center for Basic Metabolic Research, Section on
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shivering thermogenesis. PR domain Zink Finger Protein (PRDM)-16
has been shown not only to control the brown fat cell development [7],
but also to drive the thermogenic program in white adipocytes both
in vivo and in vitro [8,9]. Conversely, Zink Finger Protein (ZFP)-423,
initially found to control preadipocyte determination by regulating Pparg2
expression [10], was recently shown to suppress the thermogenic
program, including Ucp1 expression, in mature adipocytes [11]. Thus,
the expression of key thermogenic genes such as Ucp1 can be
controlled, at least partially, by a potent regulatory-signaling driven
by Prdm16 or Zfp423. However, the complex processes involved in
adipocyte commitment/maintenance, and particularly the synergistic
effects of transcriptional regulators, are still poorly understood, calling for
more accessible methods to manipulate gene expression in adipocytes.
Manipulating gene expression in pre- and mature adipocytes is
fundamental to the loss- and gain-of-function studies investigating the
role of a given gene in regulating adipogenesis or adipocyte function.
While gene silencing is generally easily achievable, several obstacles
become obvious in the conventional overexpression approaches; these
include the limiting size of the DNA construct and uncontrollable
expression levels, which often result in non-physiological concentra-
tions of the protein and thus affecting its physical properties. Addi-
tionally, manipulating gene expression in the mature adipocyte is
challenging due to inefﬁcient adenovirus-mediated gene expression
[12] associated with cytopathogenicity [13] or poor gene silencing
efﬁcacy using transfection-based siRNA delivery as observed in e.g.
3T3-L1 cells [14]. Furthermore, since retroviral-based approaches
depend on integration of the virus into the host genome, the likelihood
of perturbing endogenous genes, and thus inducing protein signaling
artifacts, must be taken into account. Although preadipocytes are
more susceptible to gene manipulations compared to mature lipid-
containing adipocytes, strategies targeting the preadipocyte to eluci-
date gene functions in the mature state should be avoided due to
possible interference with the differentiation process per se. Several
modern technical improvements indeed eased the manipulation of
gene expression in adipocytes, including electroporation [14], reverse
transfection [15], various viral-based vector delivery systems [16] and
a stable expression of the Coxsackievirus and adenovirus receptor
(CAR) [17], however, efﬁcient and easily adaptable tools allowing for
sustainable overexpression and bi-directional gene manipulation in
mature fat cells are still largely limited.
The versatile gene-editing system CRISPR-Cas9, ﬁrst used to edit the
mammalian genome [18,19], has several derived applications
including repressing (CRISPRi) or activating (CRISPRa) endogenous
genes [20]. Subtypes of the activator system rely on the enzymatically
dead Cas9 enzyme coupled to a transactional activator e often the
VP64 domain. An introduction of a single guide (sg) RNA targeting a
speciﬁc promoter allows for manifold induction of an endogenous gene
and, importantly, co-expression of multiple sgRNAs allows multiplex
gene expression [21]. Recently, more advanced and potent versions of
the CRISPRa systems have been engineered such as the Synergistic
Activation Mediator (SAM) system, in which a third component
consisting of the P65 subunit of the transcription factor NF-kB and the
activator domain found on heat-shock factor 1 form a complex with the
dCAS9-sgRNA to synergistically boost the transcription [21], making it
one of the most powerful CRISPRa types developed thus far [22].
We hypothesized that the CRISPRa SAM system can be adopted as a
tool for (co-)activation of key functional genes in preadipocytes, as well
as for manipulation of gene expression in mature adipocytes.
We showed that endogenous Pparg2-expression can be induced to
varying levels, depending on sgRNA-promoter region binding position;1314 MOLECULARMETABOLISM 6 (2017) 1313e1320  2017 The Authors. Published by Elsevier GmbH. Thimportantly this expression was sufﬁcient to promote adipogenesis and
thus functionally affect cell morphology. Furthermore, we demon-
strated that co-delivery of sgRNAs controlling the expression of
either Prdm16 or Zfp423, in combination with a Pparg2-targeting
sgRNA, inﬂuenced the differentiation towards either a more brite/beige
or white phenotype, respectively. Lastly, we showed that CRIPSRa SAM
permitted the manifold induction of endogenous genes, here Ucp1,
in mature adipocytes. This overexpression was successfully combined
with siRNA-mediated gene silencing for other targets, thereby
demonstrating efﬁcient bidirectional manipulation of gene expression
in mature fat cells after bypassing the differentiation period.
Thus, we report here a detailed in vitro protocol using easily accessible
tools to manipulate gene expression in adipocytes. The major advan-
tage of this model is that once the core components of the CRISPRa
SAM system are established, it is easy to use and allows concurrent
expression and silencing of virtually any gene of intereste either alone
or in combination e in both pre- and mature adipocytes.
2. MATERIALS AND METHODS
2.1. Reagents
C3H/10T1/2 clone 8 cells were obtained from ATCC (Wesel, Germany).
Lenti dCas9-VP64 vector (#61425), lenti MS2-P65-HSF vector (#61426)
and sgRNA cloning backbone (#61424) were from Addgene (Cam-
bridge, MA, USA). Glutamine, Hygromycin, Blasticidin, 3-Isobutyl-1-
methylxanthine (IBMX), human insulin, Rosiglitazone, Dexamethasone,
CL 316,243, and siRNA (Mission; SASI_Mm01_00036294) were
purchased from Sigma Aldrich (Brøndby, Denmark); BODIPY, DMEM-
high glucose, Penicillin-streptomycin, Sodium Pyruvate, Non-essential
amino acids, Lipofectamine 3000 reagent, Lipofectamine RNAiMAX,
DAPI (40,6-Diamidino-2-Phenylindole, Dihydrochloride) AlexaFluor 594
antibody, and ProLong Gold Antifade reagent were from Thermo Fisher
Scientiﬁc (Slangerup, Denmark); BMP2 was from R&D Systems
(Abingdon, UK); Mirus TransIT-X2 was from Kem-En-Tec (Taastrup,
Denmark); anti-mouse UCP1 antibody Cat#UCP11-A (AH Diagnostics,
Aarhus, Denmark); FCCP, Rotenone, Antimycin A, and XF assay medium
modiﬁed DMEM were from Agilent Technologies (Copenhagen,
Denmark); oligo DNAs from TagCopenhagen (Copenhagen, Denmark);
Superfect was from Qiagen (Copenhagen, Denmark), and Lenti-X
concentrator was from Clontech (Saint-Germain-en-Laye, France).
iScript was from BIO-RAD (Copenhagen, Denmark); RNeasy was from
Qiagen (Copenhagen, Denmark); Brilliant III SYBR green Master Mix was
from AH Diagnostics.
2.2. Generation of the C3H/10T1/2-CRISPRa-SAM stable cell line
Lentiviruses expressing dCas9-VP64 and MS2-P65-HSF1 were
generated in 293 cells by co-transfection of the packaging plasmids
psPAX.2 and psMD2.g using Superfect transfection reagent. Virus-
containing supernatant was harvested 72 h post transfection and
concentrated using Lenti-X concentrator. Sub-conﬂuent C3H/10T1/2
cells were subsequently exposed to virus (with polybrene; 8 ug/ml) and
selected with blasticidin (2.5 ug/ml) and hygromycin (200 ug/ml).
Expression of the two components was veriﬁed using RT-qPCR. The
resulting cell-line stably expressing the SAM components was termed
“C3H/10T1/2-CRISPRa-SAM”.
2.3. Single guide (sg)RNA design and cloning
sgRNAs were designed using the online tool: http://sam.genome-
engineering.org/database/ and cloned into the backbone vector
according to Konermann et al. [21]. Correct insertion was veriﬁed by
sequencing. sgRNA sequences: Prdm16; GCGGCGGCGGCGCGACGAAG,is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Zfp423; GAGGAGGGTGAGGGTGGCGG, Ucp1; GGGAGTGACGCGCGG
CTGGG. Pparg2 sgRNAs are listed in Figure 1A.
2.4. Transfection of pre- and mature adipocytes
45,000 C3H/10T1/2-CRISPRa-SAM cells were seeded in 12-wells
and transfected with 250 ng of sgRNA per well using TransIT-X2
reagent. Evaluation of sgRNA efﬁcacy was done 48 h post trans-
fection. 2,000e4,000 C3H/10T1/2-CRISPRa-SAM cells were seeded in
the seahorse-wells and transfected with 40 ng of sgRNA per well using
TransIT-X2 reagent. For transfection of mature adipocytes, 500,000
cells were reverse transfected with 2 ug of sgRNA using TransIT-X2,
Lipofectamine- 3000 or RNAiMAX reagent. For bidirectional expres-
sion studies, a ﬁnal concentration of 50 nM siRNA targeting the pyruvate
kinase M [23] was added. Supplemental Figure 1 summarizes optimal
details for transfection of pre- and mature adipocytes with sgRNA and
siRNA allowing bidirectional manipulation of gene expression.
2.5. Cell culture and differentiation
C3H/10T1/2-CRISPRa-SAM cells were cultured in DMEM high glucose
with 10% fetal bovine serum, 1% Penicillin and Streptomycin, Blas-
ticidin, and Hygromycin. For differentiation of C3H/10T1/2-CRISPRa-
SAM cells with Pparg2 sgRNA, cells were given Rosiglitazone (5 mM)
every other day starting 2 days after transfection. For co-expression
studies Rosiglitazone (5 mM) was only added for 48 h following
transfection. For transfection of mature adipocytes, C3H/10T1/2-
CRISPRa-SAM cells were pre-treated with BMP2 (100 ng/ml) for four
days, and differentiation was induced at conﬂuence by Dexametha-
sone (5 mM), IBMX (500 mM), insulin (0.85 mM), and Rosiglitazone
(1 mM) for two days followed by insulin (0.85 mM) and Rosiglitazone
(1 mM) for another two days; at this point, the differentiated cells wereFigure 1: Regulating endogenous Pparg2 expression and adipogenesis. (A) Pparg2
induction of Pparg2 expression two days post transfection in the C3H/10T1/2-CRISPRa-S
ferentiation of C3H/101/2-CRISPR-SAM cells using Pparg2 sgRNA or empty vector (EV) sti
(green) and DAPI (blue) staining or (D) RT-qPCR of the adipogenic markers Ap2 and Adipon
Dunnett’s test, *p < 0.05 versus EV transfected cells (B) or versus the Pparg2 sgRNA tr
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complete media (DMEM, 12% FBS, 1% Penicillin and Streptomycin,
1% extra Glutamine, 1% non-essential amino acids, 1% Sodium
Pyruvate). For BODIPY/DAPI staining of pre- and mature adipocytes,
BODIPY (0.1 ug/ml) and DAPI (0.5 ug/ml) were diluted in DMEM without
serum and incubated for 30 min.
2.6. Quantitative PCR
RNA was extracted using RNeasy and cDNA synthesized using the
iScript kit according to the manufacturer’s instructions. Real-time PCR
was performed using the CFX384 Real-Time System according to the
supplier’s manual (Bio-Rad). Each cDNA sample was run in duplicates
and raw data were normalized to house keeping genes (18S or Tbp).
Primer sequences are described in Supplemental Table 1.
2.7. Oxygen consumption
Real-time measurements of oxygen consumption rates (OCR)
were performed using a Seahorse XF96 Extracellular Flux Analyzer
(Agilent Technologies). The cell culture medium was changed 1 h
before the ﬁrst measurement to XF assay medium modiﬁed
DMEM (Agilent Technologies) supplemented with 5 mM glucose and
2 mM L-glutamine and adjusted to pH 7.4. OCR was measured under
basal conditions and after injection of 5 mM CL 316,243, 1 mM FCCP
and 1 mM Rotenone combined with 1 mM Antimycin A. Area under the
curve (AUC) was calculated from the time of the CL 316,243 injection
(uncoupling) or the FCCP injection (maximal respiratory capacity).
2.8. Flow cytometry
Adipocytes were stained with BODIPY and DAPI for 30 min before
trypsinization and resuspended in PBS þ 1% BSA. Cells were forcedsgRNA sequences, distance to transcription start site (TSS) and fold induction. (B) Fold
AM cells using different sgRNAs binding distinct places on the Pparg2 promoter. Dif-
mulated with 5 mM Rosiglitazone or vehicle (DMSO) for 8 days assessed by (C) BODIPY
ectin and Pparg2. Data are presented as means þ SEM, n ¼ 3, One-way ANOVA with
ansfected cells treated with Rosiglitazone (D).
pen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1315
Brief Communicationthrough a cell-strainer and gated according to BODIPY intensity on a
BD FACS Aria III sorter.
2.9. Immunocytochemistry
After trypsinization, cells were reseeded during the reverse transfection
on gelatin-coated coverslips. Two days post-transfection, cells were
ﬁxed in 4% paraformaldehyde, permeabilized (0.1% Triton-X in PBS),
and blocked (1% FBS in PBS) prior to primary antibody (1:400) incubation
overnight in a humidiﬁed chamber at 4 C. UCP1 protein was visualized
using a secondary AlexaFluor 594 antibody (1:1000) for 1 h at room
temperature. Cells were counter-stainedwith BODIPY for 30min at room
temperature and DAPI (300 nM in PBS) for 10 min at room temperature
for lipid and nuclear detection, respectively. Coverslips were mounted on
glass slides with ProLong Gold Antifade. Imaging was performed using a
confocal microscope (Zeiss LSM 780) with 20 water-immersion
or 63 oil-immersion lenses; images were captured in Z-stacks (16e
24 stacks per image; ZEN Black software) using identical exposure
settings throughout conditions for qualitative comparisons.
2.10. Statistical analyses
All data are presented as means þ SEM. Comparisons between
groups were carried out by ANOVA followed by Dunnett-corrected
or Sidak-corrected multiple comparisons or Bonferroni-corrected
Student’s t-test using Prism (GraphPad). P-values below 0.05 were
considered signiﬁcant.
3. RESULTS
To increase the expression of endogenous genes in pre- and
mature adipocytes, we ﬁrst established a C3H/10T1/2 MSC line stably
expressing the two core components of the SAM system
(Supplemental Figure 2); the cell-line is here after referred to as “C3H/
10T1/2-CRISPRa-SAM”.
3.1. CRISPRa-mediated overexpression of the endogenous Pparg2
gene promotes adipocyte differentiation
In an attempt to create a model of in vitro adipogenesis without the use
of any differentiation cocktail, we assessed the ability of the CRISPRa
SAM system to induce adipocyte differentiation by targeted tran-
scription of endogenous Pparg2 alone. Indeed PPARg2 is considered a
master transcription factor driving adipogenesis. In fact, ectopic
overexpression and stimulation of PPARg2 alone promotes adipo-
genesis [5]. We thus designed 5 different sgRNAs targeting different
regions of the Pparg2 promoter and tested their efﬁcacy in inducing
Pparg2 expression (Figure 1A and B). We observed varying degrees of
induction ranging fromw200 fold (sgRNA#1) to more than 12,000 fold
(sgRNA#2). A pool of all 5 sgRNAs simultaneously targeting the Pparg2
promoter did not exceed the over-expression level reached with
sgRNA#2 alone, indicating no additive effect. Substantial differentiation
was achieved in C3H/10T1/2-CRISPRa-SAM cells transfected with
sgRNA#2 and treated with the PPARg2 agonist Rosiglitazone, as
measured by BODIPY-staining (Figure 1C) and expression levels of
classic adipogenic markers such as Adipocyte protein (Ap)-2 and
AdipoQ (Figure 1D). These data show that CRISPRa SAM is effective in
controlling the expression level of endogenous genes in preadipocytes,
consequently affecting cell fate e here adipogenesis.
3.2. Multiplex gene induction inﬂuences the characteristics of
mature adipocytes
Next, we investigated whether the CRISPRa SAM system could be used
to promote or repress “brite/beige-like” characteristics by1316 MOLECULARMETABOLISM 6 (2017) 1313e1320  2017 The Authors. Published by Elsevier GmbH. Thsimultaneously targeting speciﬁc endogenous genes. As a proof of
principle, we chose the brown-promoting factor Prdm16 [9] and the
white-maintaining factor Zfp423 [11], which were previously shown to
either increase or suppress the expression of thermogenic genes in
adipocytes, respectively. We tested the efﬁcacy of 5 sgRNAs for both
Prdm16 and Zfp423 and selected the most potent guides for further
studies (data not shown). We transfected cells with sgRNAs for these
two factors either alone or in combination with the Pparg2 sgRNA#2. In
contrast to the “standard” differentiation cocktail containing Dexa-
methasone, IBMX and insulin (DMI), we induced adipogenesis by
Rosiglitazone alone speciﬁcally targeting successfully transfected cells
to differentiate. Thus, this system allows direct interrogation of the
effects of gene multiplexing within the same cell.
As shown in Figure 2AeC, the sgRNAs produced a robust induction of
Pparg2 (w4000 fold), Prdm16 (w275 fold) and a mild but signiﬁcant
up-regulation of Zfp423 (w4 fold) compared to empty vector (EV)
controls in preadipocytes 2 days post transfection. Interestingly, we
observed that the basal expression levels of both Pparg2 and Prdm16
were manifold lower than that of Zfp423 in the C3H/10T1/2-CRISPRa-
SAM cells, suggesting an inverse correlation between basal expres-
sion level and sgRNA efﬁcacy. Activation of Prdm16 or Zfp423 did
not affect overall differentiation levels in Pparg2-transfected cells, as
assessed by Ap2 and AdipoQ expression (Figure 2D and E). However,
when differentiated cells were stimulated with the b3 adrenergic
receptor agonist CL 316,243 (CL), induction of Ucp1 was signiﬁcantly
potentiated by co-activation of Prdm16 compared to Pparg2 alone,
and in contrast to Zfp423 co-expression, which blocked Ucp1 up-
regulation (Figure 2F). A similar trend was observed for Cidea
(Figure 2G). In line with these data, co-activation of Prdm16 with
Pparg2 showed increased CL-induced uncoupling and maximal res-
piratory capacity compared to co-activation of Zfp423 and Pparg2
(Figure 2H). Thus, we demonstrated that CRISPRa SAM is suitable to
be used for multiplex gene expression, and thereby for the control of
thermogenic gene expression and mitochondrial respiration in adi-
pocytes, independently of differentiation.
3.3. Regulating endogenous gene expression in mature adipocytes
Next, we aimed at utilizing CRISPRa SAM to increase gene expression
in mature adipocytes. To bypass the differentiation state, we modiﬁed
previous siRNA-based transfection protocols for mature adipocytes
[15,23]. Brieﬂy, this method utilizes reverse transfection (transfection
of cells in suspension) with siRNAs in adipocyte cell-lines 6e9
days after induction and has proven highly efﬁcient for gene silencing.
We substituted the siRNAs with sgRNAs and employed a sgRNA-
expressing plasmid targeting the Ucp1 promoter. Additionally, we
tested three different transfection reagents (Lipofectamine3000,
TransIT and RNAiMAX) for their efﬁciency to deliver the sgRNAs. Adi-
pocytes were reverse transfected 8 days after differentiation start,
followed by gene expression and immunocytochemical analyses
two days post-transfection. Importantly, to demonstrate that the Ucp1
induction indeed occurred in mature cell population, we stained cells
with BODIPY to collect low BODIPY-ﬂuorescence cells (non-adipocytes)
and high BODIPY-ﬂuorescence cells (adipocytes) by ﬂuorescence-
activated cell sorting (FACS). Preadipocytes were almost exclusively
found in the group of cells with “low” BODIPY-ﬂuorescence intensity
(Figure 3A), whereas the majority of the differentiated cells appeared in
the “high” BODIPY-ﬂuorescence intensity group (Figure 3B). Impor-
tantly, reverse transfection of the Ucp1 sgRNA led to a robust induction
of Ucp1 (more than 4  103 fold for TransIT reagent), regardless of
transfection reagent in the mature adipocytes population (Figure 3C).
Lastly, using immunoﬂuorescence against UCP1 protein, we conﬁrmedis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Co-expression of either Prdm16 or Zfp423 with Pparg2 regulates thermogenic characteristics in adipocytes. C3H/10T1/2-CRISPRa-SAM cells were transfected
with EV, Pparg2 and/or Prdm16/Zfp423 sgRNAs. Expression of (A) Pparg2, (B) Prdm16, (C) Zfp423, (D) Ap2, and (E) AdipoQ were assessed by RT-qPCR. To stimulate the
expression of thermogenic genes, C3H/10T1/2-CRISPRa-SAM cells were treated with 5 mM CL 316,243 for 6 h and (F) Ucp1 and (G) Cidea expression assessed by RT-qPCR.
Oxygen consumption was assessed using Seahorse (H). Data are presented as means þ SEM, n ¼ 4 (n ¼ 3 for Seahorse data), ANOVA with Dunnett’s (AeE) or Sidak-
corrected test (H) or Bonferroni-corrected Student’s t-tests (F þ G), *p < 0.05, **p < 0.01, ***p < 0.001 versus the Pparg2 sgRNA transfected cells.that reverse transfection of the Ucp1-sgRNA indeed leads to
up-regulation of UCP1 protein levels in mature adipocytes, with
UCP1 immunoreactivity predominantly detected in lipid-laden BODIPY-
positive cells transfected with Ucp1 sgRNA (Figure 3D, Supplemental
Videos 1AþB). Hence, CRISPRa SAM is appropriate for endogenous
RNA and protein overexpression in mature adipocytes. Of note,
delivering sgRNAs as U6-expression cassettes [24], thereby reducing
the size from w3 kb to just w430 bp, resulted in the induction of
Ucp1 expression, although the efﬁcacy was lower compared to the
plasmid-based delivery (Supplemental Figure 3).
Supplementary videos related to this article can be found online at
http://dx.doi.org/10.1016/j.molmet.2017.07.001.
3.4. Bidirectional gene regulation in mature adipocytes
Almost any change in cell homeostasis is a net result of changes in
numerous genes being either induced or repressed. Therefore, we
tested whether the CRISPRa SAM system could be used in combination
with gene silencing using siRNA in mature adipocytes. As an example,
we used the Ucp1 sgRNA in combination with siRNAs targeting
pyruvate kinase M (Pkm), which we have previously shown to be
efﬁcient in mature adipocytes [23]. We also tested the efﬁcacy of the
three transfection reagents described in Figure 3 to efﬁciently deliver
both sgRNAs and siRNAs in mature cells. As shown in Figure 4A, Ucp1
expression was robustly and equally induced following transfection of
its sgRNA using any of the transfection reagents. However, the level of
Pkm knockdown was dependent on the transfection reagent. Indeed,
89% and 83% knockdown of Pkm were obtained with TransIT and
RNAiMAX, respectively, when combined with Ucp1 overexpression,
whereas Lipofectamine 3000 produced a 49% reduction. These dataMOLECULAR METABOLISM 6 (2017) 1313e1320  2017TheAuthors. Published by ElsevierGmbH. This is an o
www.molecularmetabolism.comdemonstrate that bidirectional gene expression can be achieved by
combining the CRISPRa SAM system with siRNAs in the same
transfection when a compatible transfection reagent is used.
4. DISCUSSION
Genetic loss- and gain-of-function studies are invaluable to elucidate
the function of genes and proteins. Gene silencing using RNAi
revolutionized loss-of-function studies and has been extensively used
to study adipocyte biology [14,25]. However, gene overexpression has
remained a challenge, especially in mature adipocytes, due to poor
plasmid delivery and time-consuming experimental procedures such
as subcloning and virus production. Other pitfalls such as gene size
limitations and lack of control over the ectopic expression level further
complicate the feasibility of overexpression studies.
While CRISPRa has some drawbacks including limited activation of
genes with high baseline expression [21,22], and possible sgRNAs
off-targets similar to RNAi-based strategies relying on complementary
nucleotides should not be ignored, a number of advantages greatly
favor this technique. Indeed, we show here that CRISPRa SAM allows
for overexpression of endogenous genes for which the level of over-
expression can be controlled by selecting appropriate sgRNAs of
various efﬁcacies. Importantly, we also demonstrated that CRISPRa
SAM can be applied in mature adipocytes, thus overcoming many
caveats of the existing conventional overexpression tools. It is of in-
terest that different levels of expression can be achieved by selecting
different sgRNAs (e.g. Pparg2 from w200-fold to w12,000-fold
compared to EV controls); as this allows to adjust the induction of a
given gene of interest to mirror a physiological or pathological situation.pen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1317
Figure 3: Induction of Ucp1 mRNA and protein in mature adipocytes. C3H/10T1/2-CRISPRa-SAM cells were differentiated to mature adipocytes and reverse transfected with
Ucp1 sgRNA or EV. Cell sorting was used to select mature adipocytes. (A) Preadipocytes stained with BODIPY elicited a “low” BODIPY-ﬂuorescence intensity compared to (B)
mature adipocytes. (C) After reverse transfection the mature adipocyte fraction was collected and endogenous Ucp1 expression examined by RT-qPCR. (D) Mature adipocytes,
reverse-transfected with either EV or Ucp1 sgRNA, were ﬁxed and stained for UCP1 protein expression (red), nuclei (blue) and lipids (green) using immunoﬂuorescence and
BODIPY/DAPI staining. 20 and 63 magniﬁcations are shown. n ¼ 3e4, Bonferroni-corrected Student’s t-test, **p < 0.01 versus EV transfected cells.
Brief CommunicationFurthermore, endogenous promoters frequently control several
isoforms of the same gene, including intronic microRNAs [26]. Thus,
the CRISPRa should allow the induction of all promoter-based products,
mimicking the activation of a biological pathway to a largely better
extent compared to ectopic overexpression of an isoform of interest.
Here, not only did we prove that CRIPSRa SAM is a useful tool to
overexpress genes in adipocyte cell-lines, we also provided a model
of controlling brite/beige-like characteristics such as induction of Ucp1
expression and increased mitochondrial respiration. To study key
adipogenic genes, we chose the C3H/10T1/2 cells, which were
established in 1972 from clone 8 derived from mouse embryo cells
[27]. This is an MSC cell line with the potential to differentiate into both
myoﬁbers [28] and adipocytes with either white or brown character-
istics e.g. through treatment with the BMP cytokines such as BMP2,-4
or -7 [29e31]; however, any adipocyte cell-line may be engineered to
express the two CRISPRa SAM components. Based on the work by
Tontonoz, Hu, and Spiegelman [5], in which they elegantly demon-
strated that retroviral delivery of Pparg2 was sufﬁcient to drive adi-
pogenesis in NIH 3T3 cells, we reproduced this ﬁnding through
overexpression of the endogenous Pparg2 gene. Furthermore, by
manipulating the endogenous expression of either Prdm16 [9] or
Zfp423 [10], we provide an accessible, easy, and quick system for
manipulating brite/beige-like characteristics without exogenous gene
delivery, hence yielding higher physiological relevance. Indeed, the
robust induction of Prdm16 potentiated the effect of CL-treatment on
both Ucp1 and Cidea expression, whereas Zfp423 overexpression
repressed it.
Interestingly, PRDM16 was recently shown to drive Ucp1 expression
through binding to the subunit MED-1 of the Mediator complex at the1318 MOLECULARMETABOLISM 6 (2017) 1313e1320  2017 The Authors. Published by Elsevier GmbH. Th2.5 kb upstream enhancer [32]. Whether a similar mechanism lies
behind the induction of Cidea is currently not known. Gupta et al. [10]
also showed that similarly to Prdm16 [7], ectopic expression of Zfp423
drives Pparg2 expression. We observed a similar trend (Figure 2A);
however, this was not sufﬁcient to induce differentiation in this cell line
as measured by Ap2 and AdipoQ expression.
Of note, ectopic expression of MyoD1 in C3H/10T1/2 cells has been
shown to drive myogenesis [33]. Thus, similarly to this Ppargg2-driven
adipogenic commitment model, overexpression of MyoD1, and/or (co-)
expression of novel myogenic players in C3H/10T1/2-CRISPRa-SAM
cells may provide a suitable model to assess whether a given target
affects myogenic processes in this cell line.
The multiplex feature of CRISPRa allows better interrogation of novel
gene/protein targets and high throughput-based data, including
commonly used OMICs-based discoveries to predict key pathways
regulated in a given physiological or pathological condition of interest.
The majority of validation/follow-up studies seek causation by
addressing the action of one selected target, either through over-
expression and/or knockdown; however, this may be too simplistic e
as illustrated by the necessity of co-ectopic expression of PPARg/RXRa
with PRDM16 to uncover the full transcriptional capacity of PRDM16
[7]. In stark contrast to the standard single gene-targeted approach, our
method grants synergistic and bidirectional gene expression in both
pre- and mature adipocytes allowing for more sophisticated experi-
mental designs to study complex multi-player signaling pathways such
as adipogenesis, in which a multitude of genes is regulated for the
process to occur [34]. Complementing a modiﬁed CRISPRa approach to
allow gene activation and gene knockout simultaneously [35], our
method is the ﬁrst to combine CRISPRa with siRNA, thereby allowingis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: Bidirectional gene regulation in mature adipocytes. C3H/10T1/2-CRISPRa-SAM cells were differentiated to mature adipocytes and reverse transfected with a
combination of Ucp1 sgRNA, EV sgRNA, Pkm siRNA, or a negative control siRNA. Expression of (A) Ucp1 and (B) Pkm were measured by RT-qPCR. Data are presented as
means þ SEM, n ¼ 3, one-way ANOVA with Dunnett’s test, *p < 0.05, **p < 0.01, ***p < 0.001 versus EV transfected cells with same transfection reagent.easy to use, efﬁcient, and reversible gene manipulation without altering
the genome. Employing the simultaneous and bi-directional gene
expression manipulation tool we described here, therefore, can serve
as a powerful resource for assessing the role of key target genes
involved in the regulation of adipocyte cell fate and function.
5. CONCLUSION
We report a methodological advancement using a combination of
simple and robust tools to selectively increase the expression of
endogenous genes in both pre- and mature adipocytes. We propose it
to be used not only as an alternative method to current gain-of-function
studies in vitro, but also as a new method for studying bidirectional
gene expression. From a therapeutic standpoint, the CRISPRa system
also yields a high potential for clinical applications since it does not
require changes in the host genome.
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